Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

N/A

3(37.5%)

Phase 1

3(37.5%)

Phase 2

1(12.5%)

Phase 3

1(12.5%)

8Total

N/A(3)

Phase 1(3)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06674499Not ApplicableActive Not Recruiting

Development and Evaluation of a Self-Management Model for Cancer Rehabilitation

Role: lead

NCT07100210Phase 1Recruiting

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

Role: lead

NCT07307404Not ApplicableRecruiting

Web-based Platform for Nutrition Management in Patients With Cancer

Role: lead

NCT06332664Not ApplicableCompleted

Collaborative Tele-Nutritional Care for Patient With Stage IV Cancer

Role: lead

NCT06878612Phase 1Recruiting

a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors

Role: lead

NCT05805800Phase 3Completed

Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV

Role: lead

NCT06939582Phase 1Recruiting

Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis

Role: lead

NCT04399785Phase 2Unknown

Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

Role: lead

All 8 trials loaded